E
Sell
9/23/2024Downgrade
Mangoceuticals, Inc. (MGRX) was downgraded to E+ from D- on 9/23/2024 due to a decline in the total return index and volatility index.
D
Sell
9/6/2024Upgraded
Mangoceuticals, Inc. (MGRX) was upgraded to D- from E+ on 9/6/2024 due to an increase in the volatility index.
E
Sell
8/21/2024Downgrade
Mangoceuticals, Inc. (MGRX) was downgraded to E+ from D- on 8/21/2024 due to a decline in the volatility index and total return index.
D
Sell
8/16/2024Upgraded
Mangoceuticals, Inc. (MGRX) was upgraded to D- from E+ on 8/16/2024 due to an increase in the volatility index and total return index.
E
Sell
7/31/2024Downgrade
Mangoceuticals, Inc. (MGRX) was downgraded to E+ from D- on 7/31/2024 due to a decline in the volatility index.
D
Sell
7/12/2024Upgraded
Mangoceuticals, Inc. (MGRX) was upgraded to D- from E+ on 7/12/2024 due to an increase in the valuation index, volatility index and total return index.
E
Sell
12/1/2023Upgraded
Mangoceuticals, Inc. (MGRX) was upgraded to E+ from E on 12/01/2023.
E
Sell
9/1/2023Upgraded
Mangoceuticals, Inc. (MGRX) was upgraded to E from E- on 9/1/2023 due to a large increase in the growth index and total return index. Total revenue increased 40.22% from $100.7 to $141.2, earnings per share increased from -$0.2275 to -$0.1448, and EBIT increased 6.3% from -$2.02M to -$1.89M.
E
Sell
6/14/2023None
Mangoceuticals, Inc. (MGRX) was downgraded to E- from U on 06/14/2023.
